Literature DB >> 14625046

Serum-free production and column purification of adeno-associated virus type 5.

Richard H Smith1, Chuantian Ding, Robert M Kotin.   

Abstract

Viral vectors derived from adeno-associated virus (AAV) are rapidly becoming the vehicles of choice for gene therapy applications. AAV-2 is the adeno-associated virus serotype most commonly employed in AAV-mediated gene therapy studies; however, recently developed vectors derived from alternative serotypes of AAV, such as AAV-5, are receiving special attention due to their disparate tissue tropisms and potential for serial administration. In this report, we describe a rapid and efficient method for the serum-free production and column purification of recombinant AAV-5 particles. This method utilizes a combination of anion-exchange chromatography and gel filtration chromatography to purify recombinant AAV particles to near homogeneity. Importantly, viral particles are captured directly from cellular extracts with high efficiency, and vector purification is achieved in less than one working day with a minimal amount of sample manipulation. The method described in this report does not require partial purification by density centrifugation, detergent treatment, or solvent extraction to achieve efficient levels of column binding and vector purification.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14625046     DOI: 10.1016/j.jviromet.2003.09.002

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  15 in total

1.  Scalable generation of high-titer recombinant adeno-associated virus type 5 in insect cells.

Authors:  Masashi Urabe; Takayo Nakakura; Ke-Qin Xin; Yoko Obara; Hiroaki Mizukami; Akihiro Kume; Robert M Kotin; Keiya Ozawa
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Evaluation of a Serum-free Medium for the Production of rAAV-2 using HeLa Derived Producer Cells.

Authors:  C Jenny; E Toublanc; O Danos; O-W Merten
Journal:  Cytotechnology       Date:  2005-09       Impact factor: 2.058

3.  A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells.

Authors:  Richard H Smith; Justin R Levy; Robert M Kotin
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

4.  Influence of peptide ligand surface density and ethylene oxide spacer arm on the capture of porcine parvovirus.

Authors:  Caryn L Heldt; Patrick V Gurgel; Lee-Ann Jaykus; Ruben G Carbonell
Journal:  Biotechnol Prog       Date:  2009 Sep-Oct

Review 5.  Transient transfection methods for clinical adeno-associated viral vector production.

Authors:  J Fraser Wright
Journal:  Hum Gene Ther       Date:  2009-07       Impact factor: 5.695

Review 6.  Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology.

Authors:  Alejandro Negrete; Robert M Kotin
Journal:  Brief Funct Genomic Proteomic       Date:  2008-07-16

7.  Production of recombinant adeno-associated vectors using two bioreactor configurations at different scales.

Authors:  Alejandro Negrete; Robert M Kotin
Journal:  J Virol Methods       Date:  2007-07-02       Impact factor: 2.014

Review 8.  Manufacturing of recombinant adeno-associated viral vectors for clinical trials.

Authors:  Nathalie Clément; Joshua C Grieger
Journal:  Mol Ther Methods Clin Dev       Date:  2016-03-16       Impact factor: 6.698

9.  Identification of an adeno-associated virus binding epitope for AVB sepharose affinity resin.

Authors:  Qiang Wang; Martin Lock; Andrew J Prongay; Mauricio R Alvira; Boris Petkov; James M Wilson
Journal:  Mol Ther Methods Clin Dev       Date:  2015-11-04       Impact factor: 6.698

10.  A scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform.

Authors:  Laura Adamson-Small; Mark Potter; Darin J Falk; Brian Cleaver; Barry J Byrne; Nathalie Clément
Journal:  Mol Ther Methods Clin Dev       Date:  2016-05-11       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.